Dry Eye Syndrome Market Size & Share, by Type (Evaporative, Aqueous); Diagnosis (Schirmer Test, Eye Exam); Treatment (Nutritional Supplements, Surgery); End-user (Hospitals, Eye Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 4587
Published Date: Feb 23, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Dry Eye Syndrome Landscape

Lumenis Be Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Johnson & Johnson Services Inc.
Alcon Vision LLC
Allergan (AbbVie)
Novartis AG
Allostera Pharma Inc.
I-Med Pharma Inc.
Acadia Pharmaceutical Inc.
Otsuka Pharmaceutical Co. Ltd.
Sun Pharmaceutical Industries Ltd.

Browse Key Market Insights with Data Illustration:

Dry Eye Syndrome Market Size & Share, Growth Forecasts 2035

In the News

Alcon launched its latest innovation, Systane iLux2 MGD Thermal Pulsation system, it enhances the dry eye care. This new imaging technology capture HD videos and infrared photos and enables patients to have better understanding about their problem.
Novartis AG announced the acquisition of Xiidra, the first ever prescription approved to treat the early signs and symptoms of dry eye problems by preventing inflammation caused by the disease.

Frequently Asked Questions (FAQ)

Surging count of people using contact lenses, and rising prevalence of dry eye syndrome are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023-2035.

Several nations lack effective health insurance programmes, and higher cost of the treatment is estimated to challenge the market growth.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Johnson & Johnson Services Inc., Alcon Vision LLC, Allergan (AbbVie), Novartis AG, Allostera Pharma Inc., I-Med Pharma Inc., Acadia Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., and others

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, treatment, end user, diagnosis, and by region.

The eye clinics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Dry Eye Syndrome Market Size & Share, by Type (Evaporative, Aqueous); Diagnosis (Schirmer Test, Eye Exam); Treatment (Nutritional Supplements, Surgery); End-user (Hospitals, Eye Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Companies Dominating the Dry Eye Syndrome Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the dry eye syndrome market?

What would be the CAGR of dry eye syndrome market over the forecast period?

What are the challenges affecting the dry eye syndrome market growth?

Which region will provide more business opportunities for growth of dry eye syndrome market in future?

Who are the major players dominating the dry eye syndrome market?

How are the company profiles selected?

What are the segments in the dry eye syndrome market?

Which segment captures the largest market size in end user in the dry eye syndrome market?